{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:30:01Z","timestamp":1790832601068,"version":"4.1.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F32 AI152296"],"award-info":[{"award-number":["F32 AI152296"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI106695"],"award-info":[{"award-number":["AI106695"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI125198"],"award-info":[{"award-number":["R01 AI125198"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI107731"],"award-info":[{"award-number":["R01 AI107731"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Host & Microbe"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.chom.2020.12.011","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T15:58:32Z","timestamp":1610639912000},"page":"13-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection"],"prefix":"10.1016","volume":"29","author":[{"given":"David R.","family":"Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan W.","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph S.","family":"Baric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chom.2020.12.011_bib1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1089\/vim.2000.13.179","article-title":"T-cell activation and induction of antibodies and memory T\u00a0cells by immunization with inactivated Japanese encephalitis vaccine","volume":"13","author":"Aihara","year":"2000","journal-title":"Viral Immunol."},{"key":"10.1016\/j.chom.2020.12.011_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02147-16","article-title":"Human CD4+ T\u00a0cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection in magnitude, hla restriction, and antigen specificity","volume":"91","author":"Angelo","year":"2017","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.chom.2020.12.011_bib3","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1016\/j.vaccine.2008.07.006","article-title":"Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice","volume":"26","author":"Babu","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.chom.2020.12.011_bib4","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.vaccine.2010.11.050","article-title":"Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial","volume":"29","author":"Beckett","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.chom.2020.12.011_bib5","first-page":"189","article-title":"Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers","volume":"65","author":"Bhamarapravati","year":"1987","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.chom.2020.12.011_bib6","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.chom.2020.12.011_bib7","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.chom.2020.12.011_bib8","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chom.2020.12.011_bib9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/vim.2006.19.10","article-title":"Development of a live attenuated dengue virus vaccine using reverse genetics","volume":"19","author":"Blaney","year":"2006","journal-title":"Viral Immunol"},{"key":"10.1016\/j.chom.2020.12.011_bib10","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1128\/JVI.01023-12","article-title":"Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family","volume":"86","author":"Bonsignori","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.chom.2020.12.011_bib11","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.chom.2020.12.011_bib12","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1016\/j.vaccine.2011.03.057","article-title":"Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines","volume":"29","author":"Capeding","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.chom.2020.12.011_bib13","doi-asserted-by":"crossref","first-page":"30648","DOI":"10.1038\/srep30648","article-title":"Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice","volume":"6","author":"Chiang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.chom.2020.12.011_bib14","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cell.2015.10.027","article-title":"Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology","volume":"163","author":"Chung","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.chom.2020.12.011_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ni.3081","article-title":"Broad and strong: the ultimate antibody to dengue virus","volume":"16","author":"Coloma","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.chom.2020.12.011_bib16","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4269\/ajtmh.17-0416","article-title":"Safety and immunogenicity of a tetravalent dengue DNA vaccine administered with a cationic lipid-based adjuvant in a phase 1 clinical trial","volume":"98","author":"Danko","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.chom.2020.12.011_bib17","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1073\/pnas.1200566109","article-title":"Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions","volume":"109","author":"de Alwis","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chom.2020.12.011_bib18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.aaa8651","article-title":"Dengue virus. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers","volume":"349","author":"Fibriansah","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.chom.2020.12.011_bib19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/emmm.201303404","article-title":"A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface","volume":"6","author":"Fibriansah","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.chom.2020.12.011_bib20","doi-asserted-by":"crossref","first-page":"29201","DOI":"10.1038\/srep29201","article-title":"Antibody-dependent enhancement of dengue virus infection in primary human macrophages; balancing higher fusion against antiviral responses","volume":"6","author":"Flipse","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.chom.2020.12.011_bib21","doi-asserted-by":"crossref","first-page":"e0004821","DOI":"10.1371\/journal.pntd.0004821","article-title":"Safety overview of a recombinant live-attenuated tetravalent dengue vaccine: pooled analysis of data from 18 clinical trials","volume":"10","author":"Gailhardou","year":"2016","journal-title":"PLOS Negl. Trop. Dis."},{"key":"10.1016\/j.chom.2020.12.011_bib22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-981-10-8727-1_5","article-title":"The molecular specificity of the human antibody response to dengue virus infections","volume":"1062","author":"Gallichotte","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.chom.2020.12.011_bib23","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.celrep.2018.10.006","article-title":"Genetic variation between dengue virus Type 4 strains impacts human antibody binding and neutralization","volume":"25","author":"Gallichotte","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.chom.2020.12.011_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00380-16","article-title":"Epitope addition and ablation via manipulation of a dengue virus Serotype 1 infectious clone","volume":"2","author":"Gallichotte","year":"2017","journal-title":"mSphere"},{"key":"10.1016\/j.chom.2020.12.011_bib25","doi-asserted-by":"crossref","first-page":"e01415","DOI":"10.1128\/mBio.01461-15","article-title":"A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies","volume":"6","author":"Gallichotte","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.chom.2020.12.011_bib26","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1016\/j.vaccine.2015.06.067","article-title":"Preclinical development of a dengue tetravalent recombinant subunit vaccine: immunogenicity and protective efficacy in nonhuman primates","volume":"33","author":"Govindarajan","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.chom.2020.12.011_bib27","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3389\/fimmu.2017.01309","article-title":"Global assessment of dengue virus-specific CD4+ T\u00a0cell responses in dengue-endemic areas","volume":"8","author":"Grifoni","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.chom.2020.12.011_bib28","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","article-title":"Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses","volume":"28","author":"Guy","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.chom.2020.12.011_bib29","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chom.2020.12.011_bib30","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/265739a0","article-title":"Antibody-enhanced dengue virus infection in primate leukocytes","volume":"265","author":"Halstead","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.chom.2020.12.011_bib31","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chom.2020.12.011_bib32","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1128\/CVI.00330-06","article-title":"Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes","volume":"14","author":"Holman","year":"2007","journal-title":"Clin. Vaccin. Immunol."},{"key":"10.1016\/j.chom.2020.12.011_bib33","doi-asserted-by":"crossref","first-page":"12907","DOI":"10.1128\/JVI.77.23.12907-12913.2003","article-title":"Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2","volume":"77","author":"Jaiswal","year":"2003","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.chom.2020.12.011_bib34","doi-asserted-by":"crossref","first-page":"E8378","DOI":"10.1073\/pnas.1714250115","article-title":"Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials","volume":"115","author":"Juraska","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chom.2020.12.011_bib35","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(20)30023-2","article-title":"Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial","volume":"20","author":"Kallas","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.chom.2020.12.011_bib36","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.aac5017","article-title":"Dengue viruses cluster antigenically but not as discrete serotypes","volume":"349","author":"Katzelnick","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.chom.2020.12.011_bib37","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.chom.2020.12.011_bib38","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1126\/science.abb6143","article-title":"Zika virus infection enhances future risk of severe dengue disease","volume":"369","author":"Katzelnick","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.chom.2020.12.011_bib39","doi-asserted-by":"crossref","first-page":"330ra36","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"Kirkpatrick","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chom.2020.12.011_bib40","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1016\/S0264-410X(00)00105-5","article-title":"A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys","volume":"18","author":"Kochel","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.chom.2020.12.011_bib41","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41564-019-0440-7","article-title":"Publisher Correction: past and future spread of the arbovirus vectors Aedes aegypti and Aedes albopictus","volume":"4","author":"Kraemer","year":"2019","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.chom.2020.12.011_bib42","doi-asserted-by":"crossref","first-page":"ftz003","DOI":"10.1093\/femspd\/ftz003","article-title":"Focused dengue vaccine development: outwitting nature's design","volume":"77","author":"Kudlacek","year":"2019","journal-title":"Pathog. Dis."},{"key":"10.1016\/j.chom.2020.12.011_bib43","doi-asserted-by":"crossref","first-page":"8922","DOI":"10.1074\/jbc.RA118.002658","article-title":"Physiological temperatures reduce dimerization of dengue and Zika virus recombinant envelope proteins","volume":"293","author":"Kudlacek","year":"2018","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.chom.2020.12.011_bib44","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1016\/j.vaccine.2012.07.043","article-title":"Immunogenicity and safety of tetravalent dengue vaccine in 2\u201311 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru","volume":"30","author":"Lanata","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.chom.2020.12.011_bib45","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1016\/j.vaccine.2015.09.101","article-title":"Preclinical and clinical development of a dengue recombinant subunit vaccine","volume":"33","author":"Manoff","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.chom.2020.12.011_bib46","doi-asserted-by":"crossref","first-page":"108226","DOI":"10.1016\/j.celrep.2020.108226","article-title":"Antigenic variation of the dengue virus 2 genotypes impacts the neutralization activity of human antibodies in vaccinees","volume":"33","author":"Martinez","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.chom.2020.12.011_bib47","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1016\/S0264-410X(00)00121-3","article-title":"Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge","volume":"18","author":"Men","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.chom.2020.12.011_bib48","doi-asserted-by":"crossref","first-page":"e1486","DOI":"10.1371\/journal.pntd.0001486","article-title":"Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization","volume":"6","author":"Messer","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.chom.2020.12.011_bib49","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1038\/s41598-017-04767-6","article-title":"In\u00a0vitro assembly and stabilization of dengue and Zika virus envelope protein homo-dimers","volume":"7","author":"Metz","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.chom.2020.12.011_bib50","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1038\/s41467-019-12677-6","article-title":"The oligomeric state of the ZIKV E-protein defines protective immune responses","volume":"10","author":"Metz","year":"2019","journal-title":"Nat Commun."},{"key":"10.1016\/j.chom.2020.12.011_bib51","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1038\/s41467-019-12677-6","article-title":"Oligomeric state of the ZIKV E protein defines protective immune responses","volume":"10","author":"Metz","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chom.2020.12.011_bib52","doi-asserted-by":"crossref","first-page":"e0006793","DOI":"10.1371\/journal.pntd.0006793","article-title":"Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype","volume":"12","author":"Metz","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.chom.2020.12.011_bib53","doi-asserted-by":"crossref","first-page":"e0005071","DOI":"10.1371\/journal.pntd.0005071","article-title":"Precisely molded nanoparticle displaying DENV-E proteins induces robust serotype-specific neutralizing antibody responses","volume":"10","author":"Metz","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.chom.2020.12.011_bib54","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/infdis\/jiw297","article-title":"Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue virus infections in healthy children and adolescents aged 2\u201316 years in Asia and Latin America","volume":"214","author":"Olivera-Botello","year":"2016","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.chom.2020.12.011_bib55","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1016\/j.vaccine.2011.07.020","article-title":"Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever","volume":"29","author":"Osorio","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.chom.2020.12.011_bib56","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.chom.2020.12.011_bib57","doi-asserted-by":"crossref","first-page":"e0180720","DOI":"10.1371\/journal.pone.0180720","article-title":"V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144","volume":"12","author":"Perez","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.chom.2020.12.011_bib58","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin. Vaccin. Immunol."},{"key":"10.1016\/j.chom.2020.12.011_bib59","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1097\/INF.0b013e3181fe05af","article-title":"Live-attenuated tetravalent dengue vaccine in dengue-na\u00efve children, adolescents, and adults in Mexico city: randomized controlled phase 1 trial of safety and immunogenicity","volume":"30","author":"Poo","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.chom.2020.12.011_bib60","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/infdis\/174.6.1176","article-title":"Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys","volume":"174","author":"Putnak","year":"1996","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.chom.2020.12.011_bib61","doi-asserted-by":"crossref","first-page":"504","DOI":"10.4269\/ajtmh.1996.55.504","article-title":"Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells","volume":"55","author":"Putnak","year":"1996","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.chom.2020.12.011_bib62","doi-asserted-by":"crossref","first-page":"e24196","DOI":"10.7554\/eLife.24196","article-title":"Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy","volume":"6","author":"Rabaa","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.chom.2020.12.011_bib63","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1038\/s41598-018-26904-5","article-title":"Dengue envelope-based 'four-in-one' virus-like particles produced using pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice","volume":"8","author":"Rajpoot","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.chom.2020.12.011_bib64","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1073\/pnas.1812055115","article-title":"Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies","volume":"116","author":"Raut","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chom.2020.12.011_bib65","doi-asserted-by":"crossref","first-page":"6927","DOI":"10.1128\/JVI.02724-07","article-title":"A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus","volume":"82","author":"Raviprakash","year":"2008","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.chom.2020.12.011_bib66","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1016\/j.vaccine.2005.03.042","article-title":"An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model","volume":"23","author":"Robert Putnak","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.chom.2020.12.011_bib67","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4269\/ajtmh.1952.1.30","article-title":"Research on dengue during world war II","volume":"1","author":"Sabin","year":"1952","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.chom.2020.12.011_bib68","doi-asserted-by":"crossref","first-page":"e0192672","DOI":"10.1371\/journal.pone.0192672","article-title":"Co-circulation of all the four dengue virus serotypes and detection of a novel clade of DENV-4 (genotype I) virus in Pune, India during 2016 season","volume":"13","author":"Shrivastava","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.chom.2020.12.011_bib69","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.3389\/fmicb.2017.02644","article-title":"Pichia pastoris-expressed bivalent virus-like particulate vaccine induces domain III-focused bivalent neutralizing antibodies without antibody-dependent enhancement in\u00a0vivo","volume":"8","author":"Shukla","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.chom.2020.12.011_bib70","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMra1110265","volume":"366","author":"Simmons","year":"2012","journal-title":"Dengue. N. Engl. J. Med."},{"key":"10.1016\/j.chom.2020.12.011_bib71","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.virol.2009.10.023","article-title":"Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy","volume":"396","author":"Simmons","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.chom.2020.12.011_bib72","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/s41590-019-0477-z","article-title":"A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection","volume":"20","author":"Slon-Campos","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.chom.2020.12.011_bib73","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chom.2020.12.011_bib74","doi-asserted-by":"crossref","first-page":"34215","DOI":"10.1038\/srep34215","article-title":"A tetravalent sub-unit dengue vaccine formulated with ionizable cationic lipid nanoparticle induces significant immune responses in rodents and non-human primates","volume":"6","author":"Swaminathan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.chom.2020.12.011_bib75","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/infdis\/jiy063","article-title":"Analyzing the human serum antibody responses to a live attenuated tetravalent dengue vaccine candidate","volume":"217","author":"Swanstrom","year":"2018","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.chom.2020.12.011_bib76","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/infdis\/jiz109","article-title":"Beyond neutralizing antibody levels: the epitope specificity of antibodies induced by National Institutes of health monovalent dengue virus vaccines","volume":"220","author":"Swanstrom","year":"2019","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.chom.2020.12.011_bib77","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00745-20","article-title":"Dimerization of dengue virus E subunits impacts antibody function and domain focus","volume":"94","author":"Thomas","year":"2020","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.chom.2020.12.011_bib78","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1073\/pnas.0600287103","article-title":"Mucosal and systemic adjuvant activity of Alphavirus replicon particles","volume":"103","author":"Thompson","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chom.2020.12.011_bib79","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1128\/CVI.00382-10","article-title":"The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2","volume":"18","author":"Vald\u00e9s","year":"2011","journal-title":"Clin. Vaccin. Immunol."},{"key":"10.1016\/j.chom.2020.12.011_bib80","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/INF.0b013e31829b8022","article-title":"Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9\u201316 year olds: a randomized, controlled, phase II trial in Latin America","volume":"32","author":"Villar","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.chom.2020.12.011_bib81","doi-asserted-by":"crossref","first-page":"e1000821","DOI":"10.1371\/journal.ppat.1000821","article-title":"Natural strain variation and antibody neutralization of dengue serotype 3 viruses","volume":"6","author":"Wahala","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.chom.2020.12.011_bib82","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.virol.2009.06.037","article-title":"Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody","volume":"392","author":"Wahala","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.chom.2020.12.011_bib83","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1128\/JVI.02129-14","article-title":"The human CD8+ T\u00a0cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes","volume":"89","author":"Weiskopf","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.chom.2020.12.011_bib84","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1128\/JVI.02298-12","article-title":"An Alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection","volume":"87","author":"White","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.chom.2020.12.011_bib85","doi-asserted-by":"crossref","first-page":"17169","DOI":"10.1038\/s41598-017-17355-5","article-title":"Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4","volume":"7","author":"Widman","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.chom.2020.12.011_bib86","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1139\/w11-137","article-title":"Eliciting cross-neutralizing antibodies in mice challenged with a dengue virus envelope domain III expressed in Escherichia coli","volume":"58","author":"Yang","year":"2012","journal-title":"Can. J. Microbiol."},{"key":"10.1016\/j.chom.2020.12.011_bib87","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.chom.2020.04.007","article-title":"Identification of dengue virus Serotype 3 specific antigenic sites targeted by neutralizing human antibodies","volume":"27","author":"Young","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.chom.2020.12.011_bib88","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1128\/jvi.61.12.4019-4022.1987","article-title":"Expression of dengue virus structural proteins and nonstructural protein NS1 by a recombinant vaccinia virus","volume":"61","author":"Zhao","year":"1987","journal-title":"J.\u00a0Virol."}],"container-title":["Cell Host & Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931312820306739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931312820306739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:24:36Z","timestamp":1761827076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931312820306739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1931312820306739"],"URL":"https:\/\/doi.org\/10.1016\/j.chom.2020.12.011","relation":{},"ISSN":["1931-3128"],"issn-type":[{"value":"1931-3128","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection","name":"articletitle","label":"Article Title"},{"value":"Cell Host & Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chom.2020.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}